TABLE 3.
Summary of findings for bilastine versus cetirizine.
| Bilastine versus cetirizine for allergic rhinitis | |||||
|---|---|---|---|---|---|
| Patient or population: Allergic rhinitisIntervention: bilastineComparison: Cetirizine | |||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | |
| Risk with placebo | Risk with bilastine | ||||
| Total nasal symptom | The mean total nasal symptom was 0 | MD 2.45 higher (4.64 lower to 9.53 higher) | — | 879 (2 RCTs) | ⊕⊕⊕⊕HIGH |
| Headache | Study population | RR 1.58(0.96–2.60) | 886 (2 RCTs) | ⊕⊕⊕⊕HIGH | |
| 67 per 1,000 | 107 per 1,000(69–165) | ||||
| Somnolence | Study population | RR 0.38(0.17–0.86) | 886 (2 RCTs) | ⊕⊕⊕⊕HIGH | |
| 72 per 1,000 | 27 per 1,000(14–52) | ||||
| Fatigue | Study population | RR 0.56(0.02–18.98) | 886 (2 RCTs) | ⊕⊕⊕⊝MODERATE a | |
| 29 per 1,000 | 16 per 1,000(1–554) | ||||
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: Confidence interval; RR: Risk ratio; MD: Mean difference.
a
The heterogeneity is 87%.
RCT, randomized controlled trial.